NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the expansion of its state-of-the-art affiliated pharmacy to include advanced non-sterile compounding capabilities for oral and topical medications. This milestone extends LifeMD’s pharmacy growth strategy by enabling its vertically integrated platform to deliver tailored therapies designed to meet evolving patient needs while improving efficiency and reducing relian ...

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly making materially false and misleading statements regarding its business and financial outlook, leading to a significant drop in share price [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased LifeMD shares between May 7, 2025, and August 5, 2025 [1][2]. - Investors have until October 27, 2025, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Allegations Against LifeMD - LifeMD is accused of overstating its competitive position and raising its 2025 guidance without properly accounting for increasing customer acquisition costs, particularly in its RexMD segment and for obesity-related drugs [3]. - Following the revelation of the true facts, LifeMD's shares plummeted by 44%, equating to a decrease of $5.31 per share in a single trading session [3].

Core Viewpoint - A class action securities lawsuit has been filed against LifeMD, Inc. for alleged securities fraud affecting investors between May 7, 2025, and August 5, 2025 [1]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements and concealed information regarding LifeMD's competitive position and financial guidance for 2025 [1]. - It is alleged that the defendants did not properly account for rising customer acquisition costs in LifeMD's RexMD segment and related to obesity treatment drugs [1]. - The statements made by the defendants about LifeMD's business operations and prospects were claimed to be materially false and misleading [1]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until October 25, 2025, to request to be appointed as lead plaintiff [2]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [2]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [3].

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly misleading investors about its business prospects during the period from May 7, 2025, to August 5, 2025 [1][2]. Group 1: Allegations and Misconduct - The lawsuit claims that LifeMD's management materially overstated the company's competitive position and recklessly raised its 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment and related to obesity treatment drugs [2]. - The defendants' statements regarding LifeMD's business operations and prospects were allegedly materially false and misleading, lacking a reasonable basis throughout the relevant period [2]. Group 2: Financial Impact - Following the announcement of its second quarter 2025 results on August 5, 2025, which indicated temporary challenges in the RexMD business, LifeMD revised its full-year 2025 revenue and adjusted EBITDA guidance, leading to a significant stock price drop of $5.31 per share, or 44.8%, closing at $6.53 on August 6, 2025 [3]. Group 3: Legal Proceedings - Shareholders interested in participating as lead plaintiffs in the class action must file their papers with the court by October 27, 2025 [4]. - The lead plaintiff will represent other class members in directing the litigation, although participation is not required to be eligible for recovery [4]. Group 4: Company Background - Robbins LLP, the law firm handling the case, has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5].

NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of LifeMD, Inc. (NASDAQ: LFMD). Shareholders who purchased shares of LFMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/lifemd-inc-loss-submission-form/?id=166931&from=3 CLASS PERIOD: May 7, 2025 to Augus ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of LifeMD, Inc. (NASDAQ: LFMD). Shareholders who purchased shares of LFMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: [email protected]Phone: ...

NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) between May 7, 2025 and August 5, 2025, inclusive. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of LifeMD, Inc. (NASDAQ: LFMD)?Did you purchase your shares between May 7, 2025 and August 5, 2025, inclusive ...

SAN FRANCISCO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- A new federal securities fraud class action lawsuit has been filed against LifeMD (NASDAQ: LFMD), alleging that the telehealth company and its executives provided investors with a misleading picture of its financial health and growth prospects. The suit, filed in in the Eastern District of New York, comes after a dramatic stock price decline in August following the company’s earnings report. The firm urges investors in LifeMD who suffered significant losses ...

SAN DIEGO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that a class action lawsuit has commenced on behalf of investors of LifeMD, Inc. (NASDAQ: LFMD) (“LifeMD” or the “Company”). The lawsuit seeks to recover losses on behalf of investors who purchased the Company’s securities between May 7, 2025, and August 5, 2025. If you purchased LifeMD securities and suffered losses, you have until October 27, 2025, to seek appointment as lead plaintiff. Investors who incurred significant losses a ...

Core Viewpoint - LifeMD, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between May 7, 2025, and August 5, 2025, impacting investors adversely [1][2]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements regarding LifeMD's competitive position and recklessly raised the company's 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment and related to obesity treatment drugs [2]. - The allegations suggest that the defendants' statements about LifeMD's business operations and prospects were materially false and misleading, lacking a reasonable basis during the relevant times [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until October 25, 2025, to request the Court to appoint them as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record, having secured hundreds of millions of dollars for shareholders over the past 20 years and is recognized as one of the top securities litigation firms in the United States [4].